頁籤選單縮合
題 名 | 新口服抗凝血劑Dabigatran=A New Anticoagulant--Dabigatran |
---|---|
作 者 | 林宛萱; 黃育芳; 壽偉瑾; | 書刊名 | 藥學雜誌 |
卷 期 | 28:4=113 2012.12[民101.12] |
頁 次 | 頁44-48 |
分類號 | 418.2321 |
關鍵詞 | 心房顫動; 中風; Dabigatran; Warfarin; Atrial fibrillation; Stroke; |
語 文 | 中文(Chinese) |
中文摘要 | 臨床上常用 warfarin作為預防心房顫動病人中風的用藥,但 warfarin不僅與許多藥品、食物產生交互作用,病人也需定期回診抽血檢測 INR (international normalized ratio),造成使用上的不便。 2010年10月,美國食品藥物管理局 (Food and Drug Administration, FDA)核准新型口服抗凝血藥品 dabigatran為非瓣膜性心房顫動病人中風的預防藥品,替不適合服用 warfarin或是服用 warfarin順從性較差的病人提供了另一個方式的選擇。 |
英文摘要 | According to the data from Department of Health, Executive Yuan of Taiwan, cerebrovascular disease has been the third of the top ten leading causes of death since 2007, just behind malignant neoplasm and heart disease. As an independent risk factor in stoke, atrial fibrillation (AF) increases the risk of stoke fivefold1. Therefore, the managements of AF include not only restoration and maintenance of sinus rhythm and ventricular rate control but, more importantly, prevention of stroke2. Warfarin is used to prevent stroke in patients with AF. However, it is inconvenient for patients to take warfarin due to poor compliance. For example, they have to be extra careful with drug-drug or food-drug interactions when warfarin is administrated. Besides, regular monitor of international normalized ratio (INR) is required. In October 19, 2010, a novel oral anticoagulant, dabigatran, was approved by the U.S. FDA for preventing stroke in patients with non-valvular AF. The result of The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) suggests that if patients with AF take dabigatran 150 mg twice daily, the risk of stroke or systemic embolism can be reduced approximately one-third compared to those take adjusted-dose warfarin5. Although dabigatran provides another choice for patients who cannot tolerate side effects of warfarin or are poor compliant, the risk of dabigatran such as bleeding, potential cumulative renal damage or lack of antidote, should still be assessed carefully in long-term use. |
本系統中英文摘要資訊取自各篇刊載內容。